Table 2.
Demographic, clinical, and laboratoristic data of patients with MS for PBMC analysis
| RR-MS patients N=9 | Healthy donors N=3 | |
|---|---|---|
| Sex, n of female (%) | 6 (66.6) | 1 (33.3) |
| Age, years (mean±SD) | 31.8±7.74 | 33.3±7.09 |
| Disease Duration, mo. (mean±SD) | 377.8±552.5 | NA |
| EDSS (mean±SD) | 1.11±0.91 | NA |
| Previous attacks, n of patients (%) | 3 (33.3) | NA |
| Relapse within 3 months, n of patients (%) | 5 (55.5) | NA |
| CSF - OB, n of patients (%) | 8 (88.9) | NA |
| ESR, mm/h (mean±SD) | 5.2±4.3 | NA |
| CRP, mg/dl (mean±SD) | 0.51±0.07 | NA |
| CSF protein, mg/dl (mean±SD) | 31.5±13.4 | NA |
| CSF glucose, mg/dl (mean±SD) | 64.3±8.5 | NA |
| IgG index (mean±SD) | 0.86±0.5 | NA |
| MRI+, n of patients (%) | 2 (22.2) | NA |
| Total GDP+, n of patients (%) | 4 (44.4) | NA |
| Encephalic GDP+, n. of patients (%) | 2 (22.2) | NA |
EDSS: expanded disability status scale; Previous attacks are intended as a number of two or more attacks preceding the study entry (day of diagnosis). Relapse within three months is intended within 3 months from the study entry (day of enrollment). CSF: Cerebrospinal Fluid; OB: Oligoclonal Bands; ESR: ErythroSedimentation Rate; CRP: C Reactive Protein; MRI+: MRI positive lesions in the spinal cord at study entry (day of diagnosis); Total and encephalic GDP+: Gadolinium phosphide-enhancing positive lesions in both spinal cord and encephalon, or only encephalon at study entry (day of diagnosis).